The formulations include Cannabis Science CT-1 and Cannabis Science MT-1, indicated for medical marijuana patients. Cannabis Science MT-1 is produced by Marisol Therapeutics, while Cannabis Science CT-1 is
Under the collaboration, to a target drug candidate selected by Ono, BioSeek is utilizing its proprietary BioMAP platform to conduct phenotypic screening, hit identification, lead optimization and clinical
The funding is intended to help gain further insights on ceramic materials, to develop a technology platform for safe dosing of opioids. The project will make use of
The new range of bioreactors has been developed for fragile adherent cell culture applications on a large scale. The Integrity bioreactors support safe and cost-efficient large-scale (large volume)
MM-121 is a fully human monoclonal antibody that targets ErbB3. The trial is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with separate
One of the achievements includes successful scale up of the Plasma Protein Purification System (PPPSTM) manufacturing platform in CNBG’s Wuhan facility. The new milestone demonstrates the robustness of
Warfarin is an oral anticoagulant agent largely recommended for treatment and prevention of thromboembolism such as cardiogenic brain embolism and venous thrombosis. The new formulation is believed to
Lipitor is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol. As per the deal, Pfizer manufactures and supplies
Idera entered licensing and collaboration deal with Merck KGaA in December 2007 for the research, development and commercialization of Idera’s TLR9 agonists, including IMO-2055, for the treatment of
BioClinica Express EDC offers standard RECIST (Response Evaluation Criteria In Solid Tumors) eCRFs that automatically calculate overall tumor response based on the data entered. A dynamic lesion form
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.